EE200300509A - Antikehad VLA-1 vastu - Google Patents

Antikehad VLA-1 vastu

Info

Publication number: EE200300509A
Authority: EE; Estonia
Prior art keywords: vla; antibodies
Prior art date: 2001-04-13

Application number

EEP200300509A

Other languages

English (en)

Inventor

D. Lyne Paul

A. Garber Ellen

W. Saldanha Jose

Karpusas Michael

Original Assignee

Biogen, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-04-13

Filing date

2002-04-12

Publication date

2004-08-16

2002-04-12 Application filed by Biogen, Inc. filed Critical Biogen, Inc.

2004-08-16 Publication of EE200300509A publication Critical patent/EE200300509A/et

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Pulmonology (AREA)
Neurology (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Wood Science & Technology (AREA)
Urology & Nephrology (AREA)
Neurosurgery (AREA)
Zoology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Biotechnology (AREA)
Otolaryngology (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Transplantation (AREA)

EEP200300509A 2001-04-13 2002-04-12 Antikehad VLA-1 vastu EE200300509A (et)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US28379401P	2001-04-13	2001-04-13
US30368901P	2001-07-06	2001-07-06
PCT/US2002/011521 WO2002083854A2 (en)	2001-04-13	2002-04-12	Antibodies to vla-1

Publications (1)

Publication Number	Publication Date
EE200300509A true EE200300509A (et)	2004-08-16

Family

ID=26962254

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP200300509A EE200300509A (et)	2001-04-13	2002-04-12	Antikehad VLA-1 vastu

Country Status (29)

Country	Link
US (7)	US7358054B2 (et)
EP (1)	EP1423431B1 (et)
JP (2)	JP4303475B2 (et)
KR (1)	KR100927670B1 (et)
CN (1)	CN1561345B (et)
AR (1)	AR036330A1 (et)
AT (1)	ATE471344T1 (et)
AU (1)	AU2002258778C1 (et)
BG (1)	BG66334B1 (et)
BR (1)	BRPI0209792B8 (et)
CA (1)	CA2443903C (et)
CZ (1)	CZ303450B6 (et)
DE (1)	DE60236735D1 (et)
EA (1)	EA006705B1 (et)
EE (1)	EE200300509A (et)
ES (1)	ES2347532T3 (et)
GE (1)	GEP20074252B (et)
HU (1)	HUP0402250A3 (et)
IL (3)	IL158376A0 (et)
IS (1)	IS6982A (et)
MX (1)	MXPA03009390A (et)
MY (1)	MY138286A (et)
NO (1)	NO20034554L (et)
NZ (1)	NZ529494A (et)
PL (1)	PL367324A1 (et)
SK (1)	SK288124B6 (et)
UA (1)	UA83791C2 (et)
WO (1)	WO2002083854A2 (et)
YU (1)	YU80903A (et)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7183387B1 (en)	1999-01-15	2007-02-27	Genentech, Inc.	Polypeptide variants with altered effector function
GEP20063774B (en) *	1999-06-01	2006-03-27	Biogen Idec Inc	Blocking Monoclonal Antibody to VLA-1 and Its Use for Treatment of Inflammatory Disorders
CZ303450B6 (cs)	2001-04-13	2012-09-19	Biogen Idec Ma Inc.	Protilátky k VLA-1, kompozice je obsahující a nukleové kyseliny, které je kódují, zpusob stanovení hladiny VLA-1 a použití pri lécení imunologického onemocnení
WO2003100033A2 (en)	2002-03-13	2003-12-04	Biogen Idec Ma Inc.	ANTI-αvβ6 ANTIBODIES
EP1715052A4 (en) *	2004-01-29	2007-10-03	Nat Inst Of Advanced Ind Scien	COMPOSITION AND METHOD FOR INCREASING GENTRANSFER EFFICIENCY
AU2006232287B2 (en)	2005-03-31	2011-10-06	Chugai Seiyaku Kabushiki Kaisha	Methods for producing polypeptides by regulating polypeptide association
WO2006124269A2 (en) *	2005-05-16	2006-11-23	Amgen Fremont Inc.	Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
WO2006133286A2 (en) *	2005-06-07	2006-12-14	Tel Hashomer Medical Research Infrastructure And Services Ltd.	Treatment of tnf antagonist-resistant inflammatory disorders and related methods
CN104072614B (zh)	2005-07-08	2017-04-26	生物基因Ma公司	抗-αvβ6 抗体及其用途
EP4342995A3 (en) *	2006-03-31	2024-05-15	Chugai Seiyaku Kabushiki Kaisha	Methods for controlling blood pharmacokinetics of antibodies
EP4218801A3 (en) *	2006-03-31	2023-08-23	Chugai Seiyaku Kabushiki Kaisha	Antibody modification method for purifying bispecific antibody
AU2013204572B2 (en) *	2006-05-25	2015-06-18	Biogen Ma Inc.	Methods of Treating Stroke
JP5496658B2 (ja) *	2006-05-25	2014-05-21	バイオジェン・アイデック・エムエイ・インコーポレイテッド	脳卒中を処置する方法
US7927590B2 (en)	2006-07-10	2011-04-19	Biogen Idec Ma Inc.	Compositions and methods for inhibiting growth of smad4-deficient cancers
EP1878747A1 (en)	2006-07-11	2008-01-16	greenovation Biotech GmbH	Glyco-engineered antibodies
EP2031064A1 (de) *	2007-08-29	2009-03-04	Boehringer Ingelheim Pharma GmbH & Co. KG	Verfahren zur Steigerung von Proteintitern
MX342551B (es)	2007-09-26	2016-10-04	Chugai Pharmaceutical Co Ltd	Region constante de anticuerpo modificada.
DK2202245T3 (en)	2007-09-26	2016-11-21	Chugai Pharmaceutical Co Ltd	A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
KR101840994B1 (ko)	2007-12-05	2018-03-21	추가이 세이야쿠 가부시키가이샤	항ｎｒ１０ 항체 및 그의 이용
CN107551270A (zh)	2008-04-11	2018-01-09	中外制药株式会社	与多个分子的抗原反复结合的抗原结合分子
TWI440469B (zh)	2008-09-26	2014-06-11	Chugai Pharmaceutical Co Ltd	Improved antibody molecules
KR20110094307A (ko) *	2008-11-13	2011-08-23	펨타 파마슈티컬스, 인크.	인간화된 항-ｉｌ-6 항체
EP3674317B1 (en)	2009-03-19	2024-12-11	Chugai Seiyaku Kabushiki Kaisha	Antibody constant region variant
US9228017B2 (en)	2009-03-19	2016-01-05	Chugai Seiyaku Kabushiki Kaisha	Antibody constant region variant
RU2011151069A (ru)	2009-05-15	2013-06-20	Чугаи Сейяку Кабусики Кайся	Анти-axl антитело
EP2481752B1 (en)	2009-09-24	2016-11-09	Chugai Seiyaku Kabushiki Kaisha	Modified antibody constant regions
CN110054692A (zh) *	2009-10-23	2019-07-26	米伦纽姆医药公司	抗gcc抗体分子及其相关组合物和方法
US10435458B2 (en)	2010-03-04	2019-10-08	Chugai Seiyaku Kabushiki Kaisha	Antibody constant region variants with reduced Fcgammar binding
NO2644698T3 (et)	2010-11-17	2018-06-02
CN107973851A (zh)	2010-11-30	2018-05-01	中外制药株式会社	与多分子的抗原重复结合的抗原结合分子
CN103370081A (zh) *	2011-02-03	2013-10-23	桑塔鲁斯股份有限公司	受试者的选择和治疗
PT3489255T (pt)	2011-02-10	2021-08-13	Roche Glycart Ag	Polipéptidos de interleucina-2 mutante
AU2012222252B2 (en)	2011-02-25	2016-08-25	Chugai Seiyaku Kabushiki Kaisha	FcgammaRIIb-specific Fc antibody
EA201892619A1 (ru)	2011-04-29	2019-04-30	Роше Гликарт Аг	Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
JP6322411B2 (ja)	2011-09-30	2018-05-09	中外製薬株式会社	複数の生理活性を有する抗原の消失を促進する抗原結合分子
TW201817745A (zh)	2011-09-30	2018-05-16	日商中外製藥股份有限公司	具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
CN104271122A (zh) *	2012-02-16	2015-01-07	桑塔鲁斯股份有限公司	抗vla1(cd49a)抗体药物组合物
MX362020B (es)	2012-04-27	2019-01-04	Millennium Pharm Inc	Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gcc.
MY174248A (en)	2012-04-30	2020-04-01	Biocon Ltd	Targeted/immunomodulatory fusion proteins and methods for making same
KR101774121B1 (ko)	2012-07-13	2017-09-01	로슈 글리카트 아게	이중특이적 항-vegf/항-ang-2 항체 및 안 혈관 질환의 치료에 있어서 이의 용도
PT2970512T (pt)	2013-03-12	2019-01-17	Biocon Ltd	Proteínas de fusão imunomoduladoras e métodos para produção das mesmas
US10035859B2 (en)	2013-03-15	2018-07-31	Biogen Ma Inc.	Anti-alpha V beta 6 antibodies and uses thereof
WO2014143739A2 (en)	2013-03-15	2014-09-18	Biogen Idec Ma Inc.	Anti-alpha v beta 6 antibodies and uses thereof
PT3050896T (pt)	2013-09-27	2021-08-24	Chugai Pharmaceutical Co Ltd	Processo para a produção de heteromultímeros de polipéptidos
MA40764A (fr)	2014-09-26	2017-08-01	Chugai Pharmaceutical Co Ltd	Agent thérapeutique induisant une cytotoxicité
EA201791366A1 (ru)	2014-12-19	2018-02-28	Чугаи Сейяку Кабусики Кайся	Антитела к c5 и способы их применения
CR20170326A (es)	2014-12-19	2017-08-22	Chugai Pharmaceutical Co Ltd	Anticuerpos antimiostatina, polipéptidos que contienen regiones fc variantes, y métodos de uso
TW202446796A (zh)	2015-02-05	2024-12-01	日商中外製藥股份有限公司	包含離子濃度依賴之抗原結合域的抗體、Fc區變體、IL-8結合抗體與其用途
KR101892883B1 (ko)	2015-02-27	2018-10-05	추가이 세이야쿠 가부시키가이샤	Il-6 관련 질환 치료용 조성물
EP3279216A4 (en)	2015-04-01	2019-06-19	Chugai Seiyaku Kabushiki Kaisha	PROCESS FOR PREPARING POLYPEPTIDE HETERO OLIGOMER
EP3394098A4 (en)	2015-12-25	2019-11-13	Chugai Seiyaku Kabushiki Kaisha	ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
MX2018007781A (es)	2015-12-28	2018-09-05	Chugai Pharmaceutical Co Ltd	Metodo para promover la eficiencia de purificacion del polipeptido que contiene la region de fragmento cristalizable (fc).
KR20180116215A (ko)	2016-03-14	2018-10-24	추가이 세이야쿠 가부시키가이샤	암의 치료에 이용하기 위한 세포상해 유도 치료제
AU2017305073B2 (en)	2016-08-05	2024-02-01	Chugai Seiyaku Kabushiki Kaisha	Composition for prevention or treatment of IL-8 related diseases
SG10201607778XA (en)	2016-09-16	2018-04-27	Chugai Pharmaceutical Co Ltd	Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
JP7185884B2 (ja)	2017-05-02	2022-12-08	国立研究開発法人国立精神・神経医療研究センター	Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
EP3655011A4 (en) *	2017-07-20	2021-03-31	University Of Virginia Patent Foundation	PROCEDURES FOR THE TREATMENT OR PREVENTION OF A NEUROLOGICAL DISORDER OF THE IMMUNE SYSTEM
CN112119090B (zh)	2018-03-15	2023-01-13	中外制药株式会社	对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法
EP3911363A1 (en) *	2019-01-14	2021-11-24	University of Virginia Patent Foundation	Use of integrin inhibitors for treatment or prevention of a neurological immunity disorder and/or nervous system injury
JP7671284B2 (ja)	2019-10-04	2025-05-01	ティーエーイーライフサイエンシーズ	Ｆｃ変異および部位特異的コンジュゲーション特性を含む抗体組成物
GB2595299B (en)	2020-05-21	2022-08-03	Mabsolve Ltd	Modified immunoglobulin FC regions

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
AU600575B2 (en)	1987-03-18	1990-08-16	Sb2, Inc.	Altered antibodies
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5859205A (en) *	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
WO1991010737A1 (en)	1990-01-11	1991-07-25	Molecular Affinities Corporation	Production of antibodies using gene libraries
US6673986B1 (en)	1990-01-12	2004-01-06	Abgenix, Inc.	Generation of xenogeneic antibodies
US6150584A (en)	1990-01-12	2000-11-21	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US6075181A (en)	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5789650A (en)	1990-08-29	1998-08-04	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5391481A (en)	1990-08-31	1995-02-21	The Trustees Of Columbia University	Antibody which is directed against and inhibits collagen binding to a VLA-1 epitope and uses thereof
DE69230142T2 (de)	1991-05-15	2000-03-09	Cambridge Antibody Technology Ltd.	Verfahren zur herstellung von spezifischen bindungspaargliedern
LU91067I2 (fr)	1991-06-14	2004-04-02	Genentech Inc	Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
US5565332A (en)	1991-09-23	1996-10-15	Medical Research Council	Production of chimeric antibodies - a combinatorial approach
WO1993013798A1 (en)	1992-01-13	1993-07-22	Biogen, Inc.	Treatment for asthma
US5733743A (en)	1992-03-24	1998-03-31	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
US6307026B1 (en)	1992-12-10	2001-10-23	Celltech Limited	Humanized antibodies directed against A33 antigen
CA2153692C (en)	1993-01-12	2011-11-08	Roy R. Lobb	Recombinant anti-vla4 antibody molecules
HK1008731A1 (en)	1993-02-09	1999-05-14	Biogen Idec Ma Inc.	Antibody for the treatment of insulin dependent diabetes
US6111598A (en)	1993-11-12	2000-08-29	Peveo, Inc.	System and method for producing and displaying spectrally-multiplexed images of three-dimensional imagery for use in flicker-free stereoscopic viewing thereof
US5827690A (en)	1993-12-20	1998-10-27	Genzyme Transgenics Corporatiion	Transgenic production of antibodies in milk
US5840299A (en)	1994-01-25	1998-11-24	Athena Neurosciences, Inc.	Humanized antibodies against leukocyte adhesion molecule VLA-4
KR100367948B1 (ko)	1994-01-25	2003-07-12	엘란 파마슈티칼스, 인크.	백혈구부착분자vla-4에대한인체화된항체
DE69518415T2 (de)	1994-04-26	2001-01-25	Kanebo, Ltd.	Arznei für rheumatoide arthritis
JPH08131185A (ja) *	1994-11-14	1996-05-28	Sumitomo Electric Ind Ltd	マウスｖｌａ−１分子に対するモノクローナル抗体
JPH08160972A (ja)	1994-12-01	1996-06-21	Sega Enterp Ltd	エフェクト制御方法、制御装置およびこれを利用したカラオケ装置
WO1996034096A1 (en)	1995-04-28	1996-10-31	Abgenix, Inc.	Human antibodies derived from immunized xenomice
GB9516399D0 (en)	1995-08-10	1995-10-11	Camelot Superabsorbents Ltd	Process for the production of water-absorbing compositions
DE69621940T2 (de)	1995-08-18	2003-01-16	Morphosys Ag	Protein-/(poly)peptidbibliotheken
EP0773288A3 (en)	1995-08-29	1997-07-09	Kirin Brewery	Chimera animal and its method of manufacture
DE19534177A1 (de)	1995-09-15	1997-03-20	Merck Patent Gmbh	Cyclische Adhäsionsinhibitoren
GB9519667D0 (en)	1995-09-27	1995-11-29	Univ Manchester	Pharmaceutical composition
DE19541844C1 (de)	1995-11-09	1997-07-24	Gsf Forschungszentrum Umwelt	Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
US6127524A (en) *	1996-10-18	2000-10-03	Dade Behring Inc.	Binding molecules and computer-based methods of increasing the binding affinity thereof
EP1500329B1 (en)	1996-12-03	2012-03-21	Amgen Fremont Inc.	Human antibodies that specifically bind human TNF alpha
CA2635352C (en)	1997-06-13	2012-09-11	Genentech, Inc.	Stabilized antibody formulation
WO1999061040A2 (en)	1998-05-22	1999-12-02	Boys Town National Research Hospital	USE OF α1β1 INTEGRIN RECEPTOR INHIBITORS AND TGF-β1 INHIBITORS IN THE TREATMENT OF KIDNEY DISEASE
DE19831710A1 (de)	1998-07-15	2000-01-20	Merck Patent Gmbh	Diacylhydrazinderivate
AU751157B2 (en)	1998-10-06	2002-08-08	Biogen Idec Ma Inc.	Crystals of the alpha 1 beta 1 integrin I-domain and their use
GEP20063844B (en)	1999-04-22	2006-06-12	Biogen Idec Inc	Using antagonist of integrin alpha-4 subunit for treatment of fibrosis
GEP20063774B (en)	1999-06-01	2006-03-27	Biogen Idec Inc	Blocking Monoclonal Antibody to VLA-1 and Its Use for Treatment of Inflammatory Disorders
WO2000078221A1 (de)	1999-06-17	2000-12-28	Kai Desinger	Chirurgische sonde zur minimal invasiven gewebeentnahme
WO2001073444A2 (en)	2000-03-28	2001-10-04	Cambridge University Technical Services Limited	Receptor/peptide crystal structure for identification of inhibitors
US8288322B2 (en)	2000-04-17	2012-10-16	Dyax Corp.	Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
DE10028402A1 (de)	2000-06-13	2001-12-20	Merck Patent Gmbh	Pyridin-2-yl-aminoalkycarbonylglycyl-beta-alanin und Derivate
US7153944B2 (en)	2000-07-31	2006-12-26	The General Hospital Corporation	High affinity integrin polypeptides and uses thereof
CZ303450B6 (cs)	2001-04-13	2012-09-19	Biogen Idec Ma Inc.	Protilátky k VLA-1, kompozice je obsahující a nukleové kyseliny, které je kódují, zpusob stanovení hladiny VLA-1 a použití pri lécení imunologického onemocnení
AU2003215298A1 (en)	2002-02-14	2003-09-04	Biogen, Inc.	Alpha1beta1 antagonists for treatment of atherosclerosis
JP5138867B2 (ja)	2002-08-01	2013-02-06	イミューノメディクス、インコーポレイテッド	α−フェトタンパク質Ｉｍｍｕ３１抗体および融合タンパク質ならびにその使用方法
US20040208870A1 (en)	2003-01-30	2004-10-21	Medimmune, Inc.	Stabilized high concentration anti-integrin alphanubeta3 antibody formulations
WO2005019200A2 (en)	2003-08-14	2005-03-03	Icos Corporation	Aryl piperidine derivatives as vla-1 integrin antagonists and uses thereof
WO2005019177A1 (en)	2003-08-14	2005-03-03	Icos Corporation	Aminopiperidine amide derivatives as vla-1 integrin antagonists and uses thereof
US7285530B2 (en)	2004-10-21	2007-10-23	Viron Therapeutics, Inc.	Use of SERP-1 as an antiplatelet agent
WO2006124269A2 (en)	2005-05-16	2006-11-23	Amgen Fremont Inc.	Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
WO2006133286A2 (en)	2005-06-07	2006-12-14	Tel Hashomer Medical Research Infrastructure And Services Ltd.	Treatment of tnf antagonist-resistant inflammatory disorders and related methods
US7612181B2 (en)	2005-08-19	2009-11-03	Abbott Laboratories	Dual variable domain immunoglobulin and uses thereof
MY149159A (en)	2005-11-15	2013-07-31	Hoffmann La Roche	Method for treating joint damage
US20080118496A1 (en)	2006-04-10	2008-05-22	Medich John R	Uses and compositions for treatment of juvenile rheumatoid arthritis
US9283260B2 (en)	2006-04-21	2016-03-15	Amgen Inc.	Lyophilized therapeutic peptibody formulations
JP5496658B2 (ja)	2006-05-25	2014-05-21	バイオジェン・アイデック・エムエイ・インコーポレイテッド	脳卒中を処置する方法
JP4951596B2 (ja)	2008-07-31	2012-06-13	株式会社日立製作所	冷却システム及び電子装置
KR20110128333A (ko)	2009-03-06	2011-11-29	제넨테크, 인크.	항체 제제
KR20170087538A (ko)	2009-12-21	2017-07-28	제넨테크, 인크.	항체 제제
CN103370081A (zh)	2011-02-03	2013-10-23	桑塔鲁斯股份有限公司	受试者的选择和治疗
EP2804208A4 (en)	2012-01-11	2015-07-29	Panasonic Ip Man Co Ltd	PRESSURE CONTACT SEMICONDUCTOR DEVICE AND METHOD FOR THE PRODUCTION THEREOF
CN104271122A (zh)	2012-02-16	2015-01-07	桑塔鲁斯股份有限公司	抗vla1(cd49a)抗体药物组合物

2002
- 2002-04-12 CZ CZ20033039A patent/CZ303450B6/cs not_active IP Right Cessation
- 2002-04-12 IL IL15837602A patent/IL158376A0/xx unknown
- 2002-04-12 BR BRPI0209792A patent/BRPI0209792B8/pt not_active IP Right Cessation
- 2002-04-12 MY MYPI20021347A patent/MY138286A/en unknown
- 2002-04-12 SK SK1374-2003A patent/SK288124B6/sk not_active IP Right Cessation
- 2002-04-12 NZ NZ529494A patent/NZ529494A/en unknown
- 2002-04-12 EP EP02728745A patent/EP1423431B1/en not_active Expired - Lifetime
- 2002-04-12 MX MXPA03009390A patent/MXPA03009390A/es active IP Right Grant
- 2002-04-12 JP JP2002582193A patent/JP4303475B2/ja not_active Expired - Fee Related
- 2002-04-12 DE DE60236735T patent/DE60236735D1/de not_active Expired - Lifetime
- 2002-04-12 UA UA20031110207A patent/UA83791C2/ru unknown
- 2002-04-12 EE EEP200300509A patent/EE200300509A/et unknown
- 2002-04-12 WO PCT/US2002/011521 patent/WO2002083854A2/en active IP Right Grant
- 2002-04-12 CN CN028118669A patent/CN1561345B/zh not_active Expired - Lifetime
- 2002-04-12 CA CA2443903A patent/CA2443903C/en not_active Expired - Lifetime
- 2002-04-12 US US10/474,832 patent/US7358054B2/en not_active Expired - Lifetime
- 2002-04-12 AR ARP020101359A patent/AR036330A1/es unknown
- 2002-04-12 KR KR1020037013452A patent/KR100927670B1/ko not_active Expired - Fee Related
- 2002-04-12 PL PL02367324A patent/PL367324A1/xx not_active Application Discontinuation
- 2002-04-12 HU HU0402250A patent/HUP0402250A3/hu unknown
- 2002-04-12 YU YU80903A patent/YU80903A/sh unknown
- 2002-04-12 ES ES02728745T patent/ES2347532T3/es not_active Expired - Lifetime
- 2002-04-12 GE GE5373A patent/GEP20074252B/en unknown
- 2002-04-12 AT AT02728745T patent/ATE471344T1/de not_active IP Right Cessation
- 2002-04-12 EA EA200301117A patent/EA006705B1/ru not_active IP Right Cessation
- 2002-04-12 AU AU2002258778A patent/AU2002258778C1/en not_active Ceased
2003
- 2003-10-08 IS IS6982A patent/IS6982A/is unknown
- 2003-10-10 NO NO20034554A patent/NO20034554L/no not_active Application Discontinuation
- 2003-10-13 IL IL158376A patent/IL158376A/en active IP Right Grant
- 2003-11-10 BG BG108340A patent/BG66334B1/bg unknown
2008
- 2008-01-16 US US12/015,213 patent/US7723073B2/en not_active Expired - Lifetime
- 2008-09-09 JP JP2008231431A patent/JP2009079047A/ja not_active Withdrawn
2010
- 2010-03-19 US US12/727,965 patent/US7910099B2/en not_active Expired - Fee Related
2011
- 2011-01-31 US US13/017,919 patent/US8084028B2/en not_active Expired - Fee Related
- 2011-06-15 IL IL213564A patent/IL213564B/en active IP Right Grant
- 2011-11-15 US US13/297,124 patent/US20120177638A1/en not_active Abandoned
2015
- 2015-01-15 US US14/597,262 patent/US9644030B2/en not_active Expired - Fee Related
2017
- 2017-03-27 US US15/470,442 patent/US10336826B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EA200301117A1 (ru)	2004-08-26
UA83791C2 (ru)	2008-08-26
BRPI0209792B1 (pt)	2017-03-28
BR0209792A (pt)	2005-04-26
AR036330A1 (es)	2004-09-01
GEP20074252B (en)	2007-12-10
BG108340A (bg)	2004-10-29
MY138286A (en)	2009-05-29
PL367324A1 (en)	2005-02-21
AU2002258778C1 (en)	2008-12-04
CN1561345A (zh)	2005-01-05
WO2002083854A2 (en)	2002-10-24
NO20034554D0 (no)	2003-10-10
WO2002083854A3 (en)	2004-04-08
ATE471344T1 (de)	2010-07-15
US20100272716A1 (en)	2010-10-28
US20170335000A1 (en)	2017-11-23
US20150299323A1 (en)	2015-10-22
US20110189177A1 (en)	2011-08-04
CA2443903A1 (en)	2002-10-24
US10336826B2 (en)	2019-07-02
US7723073B2 (en)	2010-05-25
IL213564A0 (en)	2011-07-31
US20120177638A1 (en)	2012-07-12
JP4303475B2 (ja)	2009-07-29
IL213564B (en)	2018-06-28
HUP0402250A2 (hu)	2005-01-28
JP2009079047A (ja)	2009-04-16
BRPI0209792B8 (pt)	2021-05-25
CN1561345B (zh)	2011-09-14
KR100927670B1 (ko)	2009-11-20
EP1423431A4 (en)	2005-04-27
CZ303450B6 (cs)	2012-09-19
US9644030B2 (en)	2017-05-09
CZ20033039A3 (cs)	2004-03-17
NO20034554L (no)	2003-12-15
AU2002258778B2 (en)	2008-01-17
US20040081651A1 (en)	2004-04-29
SK288124B6 (sk)	2013-09-03
KR20040062879A (ko)	2004-07-09
ES2347532T3 (es)	2010-11-02
JP2004536580A (ja)	2004-12-09
US8084028B2 (en)	2011-12-27
IS6982A (is)	2003-10-08
IL158376A (en)	2011-07-31
BG66334B1 (bg)	2013-06-28
NZ529494A (en)	2005-08-26
US20090010930A1 (en)	2009-01-08
SK13742003A3 (sk)	2004-07-07
MXPA03009390A (es)	2004-01-29
CA2443903C (en)	2018-03-20
EP1423431B1 (en)	2010-06-16
DE60236735D1 (de)	2010-07-29
EA006705B1 (ru)	2006-02-24
HUP0402250A3 (en)	2007-06-28
US7910099B2 (en)	2011-03-22
US7358054B2 (en)	2008-04-15
YU80903A (sh)	2006-05-25
IL158376A0 (en)	2004-05-12
WO2002083854A9 (en)	2003-11-06
EP1423431A2 (en)	2004-06-02
AU2002258778A2 (en)	2002-10-28

Publication	Publication Date	Title
EE200300509A (et)	2004-08-16	Antikehad VLA-1 vastu
CY2022005I1 (el)	2022-05-27	Βελτιστοποιημενα αντισωματα που στοχευουν to cd19
DK1501856T3 (da)	2013-03-25	Anti-HER2 antistofvarianter
NO20044347L (no)	2004-12-13	Anti-alfavbeta6-antistoff
NO20042388L (no)	2004-08-09	Antistoff mot CD40
EP1396500A4 (en)	2005-02-02	ANTI-TRAIL-R ANTIBODIES
DE60222658D1 (de)	2007-11-08	Monoklonaler anti-cd-40-antikörper
DK1599504T3 (da)	2015-03-09	Modificeret antistof
EE200300179A (et)	2003-08-15	Humaniseeritud LT-ß-R-i vastased antikehad
NO20041018L (no)	2004-03-10	Antistoffer mot OPGL
DK1421841T3 (da)	2007-12-17	Mejetærsker
CY2012003I2 (el)	2020-05-29	Αντισωματα που συνδεονται ανοσοειδικως προς blys
IS3021B (is)	2020-04-15	Mótefni gegn M-CSF
DE60227209D1 (de)	2008-08-07	Motor-Generator
EP1499352A4 (en)	2006-10-11	ANTI-INTERLEUKIN-9 RECOMBINANT ANTIBODIES
EP1542721A4 (en)	2007-05-02	MODIFIED "S" ANTIBODIES
EE200300569A (et)	2004-04-15	CD44v6-spetsiifilised antikehad
EP1664117A4 (en)	2008-07-16	IMMUNOGENIC
DE50205152D1 (de)	2006-01-12	Abgasturbolader
DE50200198D1 (de)	2004-02-12	Synchronisiereinrichtung
FI20011055A0 (fi)	2001-05-18	Heveiiniä sitovat monoklonaaliset vasta-aineet
DE50112267D1 (de)	2007-05-10	Synchronisiereinrichtung
ITPD20000192A0 (it)	2000-07-28	Anticorpi policlonali
ITTO20020523A1 (it)	2003-02-10	Motociclo
DE60238559D1 (de)	2011-01-20	Criptospezifische antikörper

Legal Events

Date	Code	Title	Description
2005-02-15	HC1A	Change of owner name